116 related articles for article (PubMed ID: 31522128)
1. Cerebrospinal fluid lymphocytosis: a hallmark of neurological complications during checkpoint inhibition.
Tonk EHJ; Snijders TJ; Koldenhof JJ; van Lindert ASR; Suijkerbuijk KPM
Eur J Cancer; 2019 Nov; 121():1-3. PubMed ID: 31522128
[No Abstract] [Full Text] [Related]
2. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
3. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
[No Abstract] [Full Text] [Related]
4. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis.
Bishu S; Melia J; Sharfman W; Lao CD; Fecher LA; Higgins PDR
Gastroenterology; 2021 Feb; 160(3):932-934.e3. PubMed ID: 33096100
[No Abstract] [Full Text] [Related]
6. Immunotherapy in colorectal cancer with mismatch repair deficiency.
Overman MJ
Clin Adv Hematol Oncol; 2019 May; 17(5):265-267. PubMed ID: 31188802
[No Abstract] [Full Text] [Related]
7. Dose-dependent toxicity of ipilimumab in metastatic melanoma.
Olischewsky A; De Schrijver S; Bankfalvi A; Wetter A; Zimmer L; Livingstone E; Schadendorf D; Ugurel S
Eur J Cancer; 2018 May; 95():104-108. PubMed ID: 29477367
[No Abstract] [Full Text] [Related]
8. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review.
Dupré A; Michot JM; Schoeffler A; Frumholtz L; Baroudjian B; Delyon J; Lebbe C; Lambotte O
Br J Haematol; 2020 Jun; 189(5):985-992. PubMed ID: 32243578
[No Abstract] [Full Text] [Related]
9. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
[No Abstract] [Full Text] [Related]
10. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
Coleman E; Ko C; Dai F; Tomayko MM; Kluger H; Leventhal JS
J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab plus ipilimumab in advanced renal-cell carcinoma.
Gunjur A
Lancet Oncol; 2018 May; 19(5):e232. PubMed ID: 29606588
[No Abstract] [Full Text] [Related]
12. Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients.
Heppt MV; Schlaak M; Eigentler TK; Kähler KC; Kiecker F; Loquai C; Meier F; Tomsitz D; Brenner N; Niesert AC; Thonke R; Hauschild A; Berking C
Ann Oncol; 2017 Dec; 28(12):3104-3106. PubMed ID: 28950303
[No Abstract] [Full Text] [Related]
13. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
14. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
Ali AK; Watson DE
Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab plus ipilimumab in metastatic colorectal cancer.
Gourd E
Lancet Oncol; 2018 Mar; 19(3):e139. PubMed ID: 29395861
[No Abstract] [Full Text] [Related]
16. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY
Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384
[No Abstract] [Full Text] [Related]
17. Cardiotoxicity associated with immune checkpoint inhibitors in cutaneous oncology.
Tabata MM; Choi S; Hirotsu K; Kwong B; Soleymani T
J Am Acad Dermatol; 2020 Apr; 82(4):986-994. PubMed ID: 31437546
[No Abstract] [Full Text] [Related]
18. Encephalitis induced by immune checkpoint inhibitors in metastatic melanoma: a monocentric retrospective study.
Galmiche S; Lheure C; Kramkimel N; Franck N; Boitier F; Dupin N; Turc G; Psimaras D; Aractingi S; Guégan S
J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):e440-e443. PubMed ID: 31219194
[No Abstract] [Full Text] [Related]
19. Recognizing encephalopathy in immune checkpoint inhibitor therapy: A single-center experience.
Wei D; Zhou DJ; Datta P; Taraschenko O
Cancer Med; 2021 May; 10(9):2978-2986. PubMed ID: 33660430
[TBL] [Abstract][Full Text] [Related]
20. [Immune checkpoint inhibitors and endocrinological side effects].
Jørgensen LB; Bastholt L; Yderstræde K
Ugeskr Laeger; 2017 Dec; 179(49):. PubMed ID: 29212592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
